The Product

BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development

Retrieved on: 
Thursday, May 2, 2024
Process, Microsoft Exchange Server, Genetic engineering, MSC, Exosome, Partnership, Engineering, Therapy, Regenerative medicine, Cell engineering, Mesenchymal stem cell, The Product, BSD, CGMP, Pharmaceutical industry

FREDERICK, Md., May 2, 2024 /PRNewswire-PRWeb/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.

Key Points: 
  • Together, BSD and RoosterBio deliver an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.
  • FREDERICK, Md., May 2, 2024 /PRNewswire-PRWeb/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
  • "By combining Biosolution Designs' innovative multigenic technologies with our well-established cell therapy products and scalable bioprocess manufacturing platforms, we will accelerate the clinical progression of the next generation of cell and exosome therapeutics."
  • "BSD is at the leading edge of advanced therapy engineering," said Tim Kelly, CEO of RoosterBio.